Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Panbela Therapeutics Inc (NQ: PBLA )

1.240 -0.070 (-5.34%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,334
Open 1.280
Bid (Size) 1.220 (1)
Ask (Size) 1.300 (4)
Prev. Close 1.310
Today's Range 1.220 - 1.300
52wk Range 0.3200 - 21.23
Shares Outstanding 2,957,736
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Panbela to Present at the LD Micro Investor Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Why Smith & Wesson Brands Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers Impel Pharmaceuticals Inc. (NASDAQ: IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday. 
Via Benzinga

Performance

YTD
-62.20%
-62.20%
1 Month
-5.34%
-5.34%
3 Month
-39.51%
-39.51%
6 Month
+147.31%
+147.31%
1 Year
-88.52%
-88.52%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 10, 2023
Via Benzinga
Nasdaq Moves Lower; US Crude Oil Inventories Decline Less Than Projected
Via Benzinga
Why Amarin Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Are Panbela Therapeutics Shares Trading Higher Today?
Via Benzinga
Crude Oil Up 1%; M&T Bank Posts Upbeat Q2 Results
Via Benzinga
Dow Rises Over 100 Points; Goldman Sachs Earnings Miss Estimates
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela's Diverse Pipeline Is Encouraging Amidst Challenges In Pancreatic Cancer Therapy: Analyst
Via Benzinga
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July
Via Benzinga
BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M
Via Investor Brand Network
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.